infect
one
common
complic
patient
diagnos
leukemia
serv
major
obstacl
treatment
earli
infect
common
caus
death
patient
diagnos
acut
leukemia
improv
treatment
support
care
past
decad
coupl
expand
prophylaxi
prevent
regimen
led
reduct
frequenc
sever
infect
regardless
due
part
age
cancer
popul
divers
cancer
treatment
procedur
infecti
diseas
remain
major
caus
morbid
mortal
patient
leukemia
central
line
sourc
infect
leukemia
patient
frequent
patient
develop
infect
due
breakdown
mucos
barrier
bacteria
gain
access
bloodstream
either
mucos
breakdown
central
cathet
adher
synthet
materi
develop
complex
biofi
lm
foreign
bodi
thu
becom
foci
infect
allow
bacteria
escap
immun
control
without
alter
pathogen
neutropenia
innat
immun
dysfunct
follow
postinduct
therapi
transplant
may
also
help
facilit
biofi
lm
format
develop
mucos
gvhd
facilit
bacteri
transloc
increas
risk
bloodstream
infect
guidelin
lineassoci
infect
specifi
c
recommend
transplant
recipi
review
greater
detail
sourc
linesit
bloodstream
infect
occur
therapi
leukemia
occur
commonli
fi
rst
week
line
placement
neutropenia
patient
gvhd
major
case
due
chemotherapyassoci
bacteri
transloc
mucos
site
earli
infect
patient
caus
gramposit
organ
howev
gnr
infrequ
patient
sever
mucos
lower
gastrointestin
gvhd
gnr
resist
prophylact
antibiot
increas
nontubercul
mycobacteria
ntm
rare
caus
tunneland
lineassoci
infect
line
remov
requir
cure
specifi
c
gramposit
bacteri
speci
commonli
associ
leukemia
therapi
transplant
coagulaseneg
staphylococcu
speci
con
common
caus
bacteremia
studi
staphylococcu
aureu
includ
methicillinresist
aureu
mrsa
associ
develop
treatment
gvhd
signifi
cantli
morbid
con
streptococcu
viridan
bacteremia
often
occur
follow
condit
associ
develop
septic
shock
multiorgan
failur
death
leukem
patient
high
risk
pneumonia
may
like
develop
invas
complic
enterococc
speci
particularli
vancomycinresist
enterococcu
vre
major
problem
patient
leukemia
transplant
increas
caus
bacteremia
risk
increas
prolong
hospit
highdos
steroid
gut
gvhd
prior
cephalosporin
therapi
prior
vre
colon
infect
one
common
complic
patient
diagnos
leukemia
serv
major
obstacl
treatment
earli
infect
common
caus
death
patient
diagnos
acut
leukemia
improv
treatment
support
care
past
decad
coupl
expand
prophylaxi
prevent
regimen
led
reduct
frequenc
sever
infect
regardless
due
part
age
cancer
popul
divers
cancer
treatment
procedur
infecti
diseas
remain
major
caus
morbid
mortal
patient
leukemia
leukemia
associ
mark
alter
humor
cellular
immun
enhanc
abil
microorgan
evad
detect
destruct
bone
marrow
replac
malign
cell
myeloid
lymphoid
cell
product
fall
avail
weaken
respons
pathogen
peripher
leukocyt
patient
acut
leukemia
impair
phagocytosi
lead
increas
risk
bacteri
fungal
infect
chronic
leukemia
demonstr
reduc
immunoglobulin
product
due
immun
defi
cit
uncommon
infect
primari
reason
patient
seek
care
uncontrol
uncommon
infect
known
portend
undiagnos
hematolog
malign
addit
direct
effect
treatment
lead
decrement
abil
patient
fi
ght
infect
chemotherapyassoci
marrow
toxic
unavoid
neutropenia
andor
lymphopenia
nearli
univers
therapi
acut
leukemia
protract
period
agranulocytosi
delay
recoveri
adapt
immun
common
follow
aggress
therapi
relaps
diseas
andor
condit
prior
hematopoiet
cell
transplant
hct
furthermor
alter
normal
gut
fl
ora
destruct
mucos
barrier
transfusionassoci
iron
overload
loss
skin
integr
increas
risk
infect
told
multipl
neg
effect
therapi
compromis
immun
respons
place
patient
ad
risk
sever
lifethreaten
infect
develop
prophylact
strategi
viral
bacteri
infect
well
broadspectrum
antifung
improv
prevent
treatment
option
highrisk
patient
novel
laboratori
techniqu
molecular
diagnost
viral
infect
also
allow
earlier
detect
major
infect
hematolog
support
use
colonystimul
factor
help
shorten
neutropenia
limit
infecti
complic
howev
even
diagnost
therapeut
option
evolv
novel
treatment
option
leukemia
biolog
immunemodul
therapi
expand
transplant
protocol
highrisk
patient
altern
stem
cell
donor
sourc
led
addit
immun
dysfunct
infecti
risk
surprisingli
prevent
regimen
also
led
emerg
drugresist
pathogen
mani
associ
increas
infectionrel
mortal
chapter
review
preval
infect
seen
leukemia
focu
primarili
transplantassoci
infect
review
time
infect
common
infect
organ
system
also
discuss
manag
neutropen
fever
assess
import
prevent
strategi
chapter
serv
refer
clinician
common
infecti
complic
howev
sheer
number
potenti
infect
larg
allow
comprehens
review
addit
address
topic
larg
variat
strength
clinic
evid
literatur
random
clinic
trial
evalu
treatment
prevent
infect
exampl
strongest
cytomegaloviru
cmv
fungal
infect
major
data
base
either
retrospect
clinic
studi
expert
opinion
overview
address
strength
evid
instead
refer
comprehens
guidelin
review
whenev
possibl
throughout
chapter
final
provid
care
complex
patient
recommend
close
collabor
colleagu
infecti
diseas
pulmonarycrit
care
surgeri
local
clinic
microbiolog
virolog
laboratori
patient
underli
leukemia
high
risk
infect
mani
present
primari
care
provid
infect
fi
rst
sign
underli
hematolog
malign
prolong
neutropenia
prior
transplant
also
shown
predictor
posttranspl
infecti
risk
mortal
provid
must
assess
patient
present
infect
symptom
recurr
fever
chronic
cough
skin
nodul
upper
respiratori
symptom
prior
start
treatment
patient
infecti
symptom
undergo
pretranspl
evalu
infect
may
even
requir
delay
transplant
condit
eg
respiratori
syncyti
viru
rsv
patient
also
standard
pretranspl
serolog
test
recommend
updat
guidelin
earli
period
postchemotherapi
condit
patient
abnorm
barrier
innat
respons
dramat
increas
risk
infect
signifi
cant
mucos
longterm
cathet
prolong
period
hospit
increas
risk
earli
bacteri
infect
typic
associ
mucos
streptococcu
speci
enter
gramneg
rod
gnr
relat
central
cathet
viral
infect
infrequ
earli
preengraft
phase
except
hsv
commonli
occur
time
frame
respiratori
pathogen
less
frequent
period
due
limit
outpati
exposur
patient
high
risk
candida
invas
mould
period
period
neutrophil
recoveri
adapt
humor
immun
respons
remain
impair
patient
continu
risk
bacteremia
gramposit
gnr
organ
viral
fungal
infect
becom
promin
cytomegaloviru
cmv
usual
occur
week
ebv
second
third
month
posttranspl
respiratori
viral
infect
increas
frequenc
move
outpati
therapi
aspergillu
candida
fungal
infect
continu
postengraft
phase
due
develop
graftversushost
diseas
gvhd
associ
treatment
day
patient
commonli
develop
infect
encapsul
eg
streptococcu
pneumonia
communityacquir
bacteri
infect
respiratori
virus
remain
major
pathogen
late
tcell
recoveri
lymphopenia
also
allow
continu
develop
cmv
viralrel
complic
varicellazost
viru
vzv
reactiv
primarili
occur
late
complic
late
fungal
infect
occur
patient
ongo
gvhd
issu
pneumocysti
jiroveci
pcp
occur
posttranspl
patient
receiv
appropri
pcp
prophylaxi
empir
therapi
neutropen
fever
leukemia
treatment
transplant
review
detail
sourc
order
address
multipl
possibl
infect
occur
treatment
leukemia
divid
infect
specifi
c
organ
system
fig
section
focu
clinic
signssymptom
differenti
diagnosi
diagnost
strategi
follow
brief
review
treatment
option
patient
develop
bloodstream
infect
present
wide
spectrum
symptom
vari
asymptomat
usual
detect
surveil
cultur
fulmin
septic
shock
patient
bloodstream
infect
usual
febril
fever
may
mask
patient
immunosuppress
particularli
highdos
steroid
hypothermia
infrequ
present
care
examin
central
venou
cathet
cvc
may
provid
visual
clue
suggest
infect
erythema
purul
around
line
exit
site
patient
may
complain
chest
wall
pain
numb
site
cathet
placement
thorough
skin
exam
also
import
patient
develop
skin
nodul
ecthyma
gangrenosum
lesion
episod
bacteremia
fungemia
develop
hypoxia
renal
insuffi
cienci
liver
function
abnorm
omin
sign
develop
septic
shock
multiorgan
failur
less
frequent
gramposit
speci
corynebacterium
jeikeium
also
caus
diseas
popul
varieti
gnr
organ
caus
bloodstream
infect
pseudomona
aeruginosa
remain
one
import
gnr
p
aeruginosa
intrins
virul
lead
addit
mortal
often
associ
highlevel
resist
stenotrophomona
maltophilia
resist
carbepenem
standard
neutropen
treatment
option
often
preferenti
select
popul
continu
emerg
multidrugresist
gnr
pathogen
provid
need
cautiou
choos
empir
regimen
organ
associ
prolong
bacteremia
increas
morbid
mortal
due
bacteri
transloc
episod
sever
mucos
gut
gvhd
enter
gnr
gramposit
clostridi
speci
frequent
particular
c
perfringen
bacteremia
lead
sever
lifethreaten
intravascular
hemolysi
c
septicum
bacteremia
associ
gastrointestin
complic
candida
speci
also
lead
bloodstream
infect
particularli
patient
either
receiv
broadspectrum
antibiot
clinic
signifi
cant
mucos
candida
speci
detect
patient
receiv
antifung
prophylaxi
like
resist
speci
particularli
c
krusei
c
glabrata
data
suggest
rate
candidemia
may
decreas
yeast
rhodotorula
less
frequent
caus
bloodstream
infect
although
mould
spread
hematogen
rare
caus
bloodstream
infect
fusarium
howev
one
mould
speci
routin
present
fungemia
typic
bananashap
conidia
seen
gram
stain
blood
cultur
pathognomon
fusariosi
site
skin
breakdown
fungal
infect
invad
damag
tissu
exit
infect
sometim
caus
fungal
pathogen
blood
cultur
mainstay
workup
patient
suspect
infect
recommend
patient
central
cathet
cultur
drawn
line
peripher
cultur
also
drawn
possibl
metaanalysi
found
line
cultur
better
diagnost
test
bacteremia
better
sensit
neg
predict
valu
compar
peripher
cultur
current
guidelin
suggest
peripher
cultur
possibl
recommend
blood
sampl
drawn
cathet
lumen
differenti
time
posit
quantit
blood
cultur
techniqu
help
identifi
catheterassoci
infect
beyond
scope
chapter
review
elsewher
line
tip
sent
cultur
time
remov
possibl
skin
biopsi
also
help
patient
suspici
skin
lesion
infect
treatment
option
vari
pathogen
site
see
tabl
tunnel
infect
requir
line
remov
exitsit
infect
sometim
manag
antibiot
therapi
particularli
associ
bacteremia
exitsit
infect
improv
system
antibiot
therapi
lead
line
remov
antibiot
therapi
bloodstream
infect
base
cultur
sensit
test
patient
repeat
cultur
assur
organ
clear
bacteri
infect
requir
least
week
iv
therapi
pathogen
eg
listeria
monocytogen
may
need
prolong
cours
patient
ntm
treat
least
month
combin
least
agent
patient
candidemia
treat
fl
uconazol
lipid
amphotericin
b
formul
echinocandin
central
cathet
remov
patient
candidemia
undergo
ophthalmolog
evalu
recommend
regard
manag
candida
infect
review
refer
pappa
et
al
decis
regard
tunnel
line
port
remov
done
collabor
infecti
diseas
intervent
radiolog
surgeri
review
mermel
patient
undergo
hct
receiv
leukemia
therapi
like
neurolog
complic
patient
undergo
hct
develop
delirium
followup
nearli
half
occur
fi
rst
week
posttranspl
infect
may
present
symptom
subtl
eg
mild
confus
rare
may
asymptomat
common
manifest
headach
memori
loss
focal
weak
imbal
patient
eye
infect
present
visual
loss
eye
pain
proptosi
chang
ocular
movement
eg
cranial
nerv
dysfunct
pupillari
chang
periorbit
edema
lead
urgent
ophthalmolog
evalu
certain
symptom
anterograd
amnesia
person
chang
classic
associ
specifi
c
infect
hsv
respect
symptom
diagnost
underli
disord
patient
sever
infect
present
omin
symptom
seizur
enceph
focal
weak
perhap
importantli
fever
may
alway
present
suggest
infecti
etiolog
sinc
patient
numer
noninfecti
etiolog
lead
cn
dysfunct
even
import
aggress
pursu
diagnosi
bacteri
infect
rel
uncommon
caus
cn
infect
age
prophylact
antibiot
standard
practic
gramneg
gramposit
organ
get
cn
lead
mening
treatment
although
rare
resist
bacteria
may
common
due
prior
antibiot
exposur
communityacquir
mening
caus
bacteria
pneumonia
infrequ
due
alter
humor
immun
emerg
microbi
resist
move
outpati
care
occur
late
posttranspl
period
treatment
ghvd
rothia
mucilaginosa
gramposit
organ
commens
organ
oral
fl
ora
associ
rare
sever
mening
occur
almost
exclus
period
sever
mucos
central
lineassoci
bacteremia
rare
lead
ophthalm
infect
caus
sightthreaten
endophthalm
brain
involv
even
less
frequent
bacteria
gain
access
intracrani
intervent
ommaya
port
placement
bacteria
known
predilect
cn
may
address
standard
prophylaxi
strategi
listeria
monocytogen
nonsporeform
gramposit
rod
commonli
acquir
foodborn
ill
particular
penchant
involv
cn
nearli
immunocompromis
patient
develop
listeriosi
develop
cn
diseas
present
acut
cerebr
brain
abscess
fig
nocardia
speci
fi
lament
bacteria
usual
lead
pulmonari
infect
develop
cn
lesion
commonli
singl
multipl
abscess
mani
cn
involv
asymptomat
time
diagnosi
routin
brain
imag
recommend
patient
diagnos
nocardia
cryptococcu
neoforman
caus
mening
immunocompromis
host
lead
occasion
infect
leukem
patient
fluconazol
prophylaxi
limit
infect
late
diseas
occur
transplant
recipi
similarli
candida
speci
ophthalm
infect
endophthalm
retin
occur
leukemia
patient
undergo
chemotherapi
transplant
cn
infect
almost
univers
associ
system
fungemia
resist
speci
c
krusei
c
glabrata
consid
patient
develop
cn
involv
prophylact
therapi
mould
infect
particularli
aspergillu
speci
also
lead
seriou
lifethreaten
cn
infect
involv
cn
usual
develop
primari
pulmonari
sourc
hematogen
spread
direct
invas
involv
sinus
mould
infect
primarili
lead
spaceoccupi
lesion
also
present
cerebr
infarct
mening
retrospect
review
brain
abscess
transplant
patient
suggest
aspergillu
common
caus
fungal
etiolog
make
close
episod
aspergillu
may
common
fungu
cn
infect
also
caus
opportunist
mould
mucoral
zygomyc
speci
scedosporium
rhinocerebr
involv
cavern
sinu
involv
uniqu
present
nearli
alway
associ
mucoral
endem
mould
histoplasma
capsulatum
coccidiodomycosi
immiti
infrequ
develop
patient
travel
resid
area
endem
latent
virus
caus
cnsrelat
diseas
particularli
patient
undergo
hct
earli
posttranspl
period
common
viral
caus
cn
infect
reactiv
usual
occur
weak
mri
brain
demonstr
abscess
yellow
arrow
surround
edema
blood
cultur
posit
gramposit
rod
later
indentifi
ed
listeria
monocytogen
symptom
improv
institut
ampicillin
gentamicin
therapi
patient
improv
prolong
cours
antibiot
week
posttranspl
symptom
rang
mild
delirium
cognit
dysfunct
seizur
enceph
varicellazost
viru
vzv
anoth
neurotrop
viru
primarili
associ
enceph
though
vasculopathi
also
associ
cn
involv
interestingli
although
vzv
reactiv
usual
present
promin
skin
involv
herp
zoster
patient
cn
diseas
may
present
without
rash
herp
simplex
hsv
enceph
also
occur
leukemia
transplant
recipi
though
patient
like
present
person
chang
focal
abnorm
addit
hsv
vzv
present
involv
otic
branch
present
unilater
facial
paralysi
ear
pain
vesicl
auditori
canal
auricl
ramsay
hunt
syndrom
cn
involv
vzv
hsv
usual
occur
discontinu
prophylact
acyclovir
prophylaxi
shown
prevent
latent
herpesviru
infect
epsteinbarr
viru
ebv
cytomegaloviru
cmv
also
caus
cn
diseas
ebv
case
associ
enceph
posttranspl
lymphoprolif
disord
ptld
polyomavirus
particularli
jc
viru
less
frequent
cn
pathogen
popul
jc
viru
caus
agent
progress
multifoc
leukoencephalopathi
pml
occur
late
posttranspl
period
present
focal
neurolog
fi
nding
alter
mental
statu
result
white
matter
demyelin
viral
pathogen
west
nile
viru
enterovirus
caus
sporad
case
cn
diseas
toxoplasmosi
commonli
found
patient
seroposit
prior
start
therapi
rare
report
patient
seroneg
toxoplasmosi
develop
posttranspl
period
nearli
case
associ
cn
involv
symptom
vari
diagnosi
diffi
cult
outcom
poor
strongyloid
stercorali
hyperinfect
occur
reactiv
clinic
silent
infect
lead
polymicrobi
mening
direct
parasit
invas
cn
patient
prior
exposur
area
high
endem
strongyloid
risk
rare
complic
mainstay
workup
cnsrelat
symptom
fi
rst
foremost
thorough
neurolog
exam
earli
fi
nding
subtl
miss
cursori
review
focal
neurolog
exam
identifi
subtl
cranial
nerv
abnorm
unsuspect
confus
andor
focal
weak
import
pay
special
attent
oropharynx
sinus
auditori
canal
nasal
passageway
lesion
locat
eg
black
eschar
vesicl
suggest
either
rout
infect
andor
specifi
c
pathogen
patient
nuchal
rigid
mental
statu
chang
fever
classic
sign
bacteri
mening
consid
urgent
lumbar
punctur
empir
antibiot
avoid
major
delay
treatment
radiolog
imag
critic
assess
highrisk
immunocompromis
patient
clinic
symptom
vari
patient
comput
tomographi
ct
magnet
reson
imag
mri
provid
import
diagnost
data
mri
provid
better
resolut
ct
scan
often
readili
avail
radiolog
imag
evalu
spaceoccupi
lesion
evid
increas
intracrani
pressur
would
preclud
cerebrospin
fl
uid
csf
analys
specifi
c
radiolog
manifest
certain
infect
herp
simplex
tempor
lobe
involv
mesial
tempor
lobe
limbic
enceph
jc
viru
singl
multifoc
white
matter
lesion
without
mass
effect
suggest
underli
diagnosi
patient
may
also
present
atyp
fi
nding
imag
toxoplasmosi
exampl
may
present
classic
ringenhanc
lesion
addit
imag
suggest
noninfecti
etiolog
lead
cn
symptom
excel
review
radiolog
fi
nding
associ
hematopoiet
transplant
review
nishiguchi
csf
analys
critic
import
diagnosi
standard
cell
count
glucos
total
protein
well
gram
stain
cultur
polymeras
chain
reaction
pcr
test
molecular
analys
potenti
lead
diagnosi
specifi
c
test
consid
csf
analysi
list
tabl
serolog
test
benefi
cial
patient
consid
risk
endem
mycos
parasit
diseas
blood
cultur
provid
addit
data
potenti
bacteri
fungal
process
patient
symptom
locat
eg
cough
undergo
addit
imag
help
complet
diagnost
workup
data
rule
noninfecti
etiolog
also
consid
drug
level
assess
cn
drug
toxic
csf
cytolog
review
fl
ow
cytometri
assess
cn
involv
leukemia
appropri
toxoplasmosi
pcr
serum
assess
patient
known
seroposit
toxoplasmosi
final
brain
biopsi
may
necessari
rare
case
make
diagnosi
due
poor
outcom
infect
occur
cn
import
consid
earli
antimicrobi
therapi
await
result
diagnost
test
delay
lead
major
morbid
sever
infect
bacteri
infect
need
aggress
iv
therapi
durat
depend
diagnosi
see
tabl
dual
therapi
cn
nocardia
speci
infect
consid
initi
eg
trimethoprim
sulfamethoxazol
imipenem
longterm
therapi
base
sensit
test
avail
length
therapi
depend
ct
resolut
feel
least
year
therapi
need
usual
antimicrobi
coverag
bacteri
mening
vancomycin
cephalosporin
aminoglycosid
treat
listeria
monocytogen
immunosuppress
patient
presum
mening
iv
ampicillin
ad
underli
empir
regimen
patient
proven
listeriosi
requir
prolong
iv
ampicillin
therapi
aspergillu
cn
infect
guid
sensit
test
possibl
usual
treatment
includ
either
voriconazol
lipid
amphotericin
b
formul
treatment
guidelin
review
walsh
et
al
voriconazol
particular
known
get
excel
cn
penetra
list
complet
inclus
decis
made
base
clinic
symptom
histori
primari
secondari
option
may
differ
depend
present
b
open
pressur
determin
time
lumbar
punctur
whenev
possibl
c
may
necessari
patient
take
prophylact
acyclovir
drug
level
depend
patient
current
medic
e
brain
biopsi
may
necessari
case
make
diagnosi
reserv
patient
sever
lifethreaten
symptom
possibl
tion
patient
cn
infect
mucoral
speci
treat
either
lipid
amphotericin
b
formul
posaconazol
overal
outcom
poor
endem
fungal
cn
infect
treatment
option
review
refer
wheat
et
al
galgiani
et
al
perfect
et
al
hsv
vzv
cn
infect
requir
highdos
iv
acyclovir
patient
enceph
receiv
either
iv
foscarnet
iv
ganciclovir
patient
toxoplasmosi
receiv
intens
therapi
pyrimethamin
sulfadiazin
folin
acid
highdos
trimethoprimsulfamethoxazol
sinopulmonari
system
one
frequent
site
infect
leukemia
therapi
symptom
vari
depend
involv
site
particularli
sinc
upper
lower
tract
infect
occur
classic
symptom
present
howev
normal
seen
immunocompet
patient
uncommon
popul
upper
tract
infect
symptom
often
involv
sinus
nasopharynx
includ
rhinorrhea
sore
throat
facial
painpressur
headach
cough
disturb
tast
smell
among
other
classic
symptom
consist
common
cold
sinus
infrequ
mild
case
develop
bloodi
black
nasal
discharg
lesion
palat
facial
weak
periorbit
erythema
proptosi
sign
sever
invas
diseas
lower
tract
parenchym
involv
symptom
may
includ
cough
sputum
product
short
breath
wheez
focal
chest
pain
hemoptysi
omin
sign
invas
fungal
infect
hypoxia
harbing
develop
acut
respiratori
distress
still
specifi
c
symptom
transplant
alway
pathognomon
specifi
c
infecti
etiolog
patient
receiv
corticosteroid
may
less
promin
symptom
occasion
patient
may
asymptomat
lesion
found
imag
noninfecti
etiolog
diffus
alveolar
hemorrhag
idiopath
pneumonia
syndrom
cryptogen
organ
pneumonia
drug
toxic
caus
symptom
even
radiograph
chang
mimic
infect
make
prompt
diagnosi
even
challeng
numer
bacteri
pathogen
lead
sinus
immunocompet
host
sinus
caus
predominantli
respiratori
pathogen
pneumonia
haemophilu
infl
uenza
moraxella
catarrhali
transplant
gnr
resist
organ
polymicrobi
infect
frequent
etiolog
patient
preexist
diseas
histori
chronic
sinu
infect
prior
transplant
like
higher
risk
specifi
c
pathogen
alway
identifi
ed
patient
treat
empir
broadspectrum
antibiot
pneumonia
caus
varieti
bacteri
organ
leukem
patient
although
transplant
bacteri
pneumonia
less
frequent
patient
prolong
neutropenia
undergo
salvag
chemotherapi
surprisingli
higher
risk
develop
complic
wide
varieti
gramposit
gnr
speci
lead
pneumonia
immunocompromis
popul
provid
awar
specifi
c
bacteri
pathogen
specifi
c
patient
gramposit
fi
lament
bacteria
nocardia
opportunist
infect
inhal
develop
pulmonari
diseas
nocardia
usual
resist
standard
antimicrobi
prophylaxi
regimen
frequent
patient
trimethoprimsulfamethoxazol
prophylaxi
receiv
steroid
nocardia
speci
vari
present
transplant
frequent
appear
nodular
pulmonari
diseas
patient
may
asymptomat
nodul
found
imag
fig
legionella
speci
also
occur
posttranspl
recipi
though
nonpneumophila
speci
particularli
l
micdadei
frequent
legionella
speci
present
lung
nodul
mimick
fungal
infect
pulmonari
infi
ltrate
mycoplasma
atyp
organ
rare
mycobacterium
aviumintracellular
mai
frequent
isol
mycobacteria
pulmonari
specimen
hct
patient
sinc
mani
colon
warrant
treatment
fungal
infect
one
common
vex
problem
patient
leukemia
hct
lead
sinopulmonari
infect
fungal
sinus
particularli
troubl
due
proxim
infect
risk
invas
cn
present
initi
similar
featur
bacteri
case
high
index
suspicion
need
prevent
lifethreaten
complic
particularli
patient
worsen
treatment
bacteri
sinus
patient
steroid
aspergillu
speci
common
caus
fungal
sinus
less
frequent
fungal
organ
scopulariopsi
paecilomyc
among
other
also
lead
sinu
diseas
mucoral
notori
lead
lifethreaten
sinu
diseas
pulmonari
fungal
infect
even
common
patient
popul
invas
aspergillu
remain
common
etiolog
patient
known
gvhd
highdos
steroid
iron
overload
cmv
infect
prolong
neutropenia
increas
risk
fungal
infect
iron
overload
particularli
associ
mucoral
may
also
preval
patient
treat
undergo
prophylaxi
voriconazol
sever
immunosuppress
multipl
fungal
speci
manifest
pulmonari
diseas
hematopoiet
transplant
recipi
yeast
less
commonli
caus
pulmonari
diseas
except
cryptococcu
speci
lead
pulmonari
nodul
although
resist
candida
speci
isol
bronchoalveolar
lavag
bal
cultur
candida
pneumonia
rare
complic
even
addit
standard
antifung
prophylaxi
uniqu
pulmonari
fungal
pathogen
patient
pcp
pcp
common
patient
highdos
steroid
receiv
discontinu
trimethoprimsulfamethoxazol
prophylaxi
diseas
usual
occur
late
complic
due
current
prevent
strategi
even
appropri
treatment
diagnost
patient
develop
pcp
develop
major
complic
multipl
viral
pathogen
lead
sinopulmonari
complic
therapi
leukemia
break
two
main
categori
reactiv
latenc
commun
acquisit
latent
herpesvirus
particularli
cmv
lead
invas
pulmonari
diseas
transplant
recipi
patient
typic
present
short
breath
hypoxia
evid
cmv
reactiv
site
risk
factor
develop
cmv
pneumonia
includ
lymphopenia
gvhd
highdos
steroid
among
other
patient
undergo
umbil
cord
blood
transplant
tcell
deplet
signifi
cantli
higher
risk
earli
cmv
pneumoniapneumon
seen
within
fi
rst
month
posttransplant
period
greatest
immunosuppress
late
cmv
diseas
occur
month
hsct
like
result
residu
defi
cit
cellmedi
immun
hsv
vzv
herpesvirus
also
rare
lead
pulmonari
complic
patient
ebvassoci
posttranspl
relat
lymphoprolif
diseas
ptld
manifest
lung
pulmonari
nodul
adenoviru
latent
lung
reactiv
posttranspl
period
lead
sever
pulmonari
complic
dissemin
respiratori
viral
pathogen
frequent
sinopulmonari
infect
patient
patient
develop
least
one
infect
mostli
upper
respiratori
event
followup
virus
caus
spectrum
diseas
includ
upper
respiratori
infect
pneumonia
andor
even
late
airfl
ow
obstruct
caus
signifi
cant
morbid
mortal
infl
uenza
b
parainfl
uenza
viru
metapneumoviru
rsv
associ
upper
sever
lower
tract
diseas
infl
uenza
virus
rsv
season
parainfl
uenza
occur
year
round
communityacquir
adenoviru
also
associ
high
rate
mortal
associ
lower
tract
diseas
rhinoviru
coronaviru
common
respiratori
viral
infect
often
limit
upper
respiratori
diseas
rare
associ
pulmonari
complic
transplant
recipi
novel
emerg
respiratori
pathogen
eg
human
bocaviru
wu
ki
polyomavirus
epidemiolog
popul
well
describ
date
radiolog
imag
sinopulmonari
system
becom
import
part
diagnost
evalu
popul
bacteri
viral
fungal
infect
opacifi
sinu
space
plain
fi
lm
ct
invas
fi
nding
boni
eros
suggest
fungal
sinus
bacteri
infect
typic
present
lobar
consolid
infi
ltrate
fungal
infect
typic
present
ct
solitari
multipl
pulmonari
nodul
classic
halo
sign
ct
suggest
underli
fungal
nodul
fig
lobar
consolid
cavitari
diseas
less
frequent
ct
present
intern
criteria
diagnosi
fungal
infect
includ
radiolog
fi
nding
help
provid
determin
patient
receiv
antifung
therapi
lower
tract
viral
infect
primarili
present
diffus
interstiti
diseas
groundglass
infi
ltrate
infect
pcp
similar
appear
pulmonari
consolid
nodular
diseas
also
describ
viral
infect
eg
cmv
hmpv
sinc
multipl
pathogen
occur
singl
patient
radiolog
fi
nding
suggest
need
confi
rmatori
test
noninvas
modal
avail
viral
fungal
infect
serum
galactomannan
gm
test
improv
diagnost
specifi
calli
aspergillu
speci
becom
import
tool
screen
serum
betad
glucan
assay
also
use
detect
fungal
infect
transplant
patient
similar
gm
assay
identifi
mucoral
speci
may
use
diagnos
pcp
serum
cryptococc
antigen
test
use
patient
cryptococcu
diagnost
possibl
cmv
adenoviru
pneumonia
typic
associ
dissemin
viremia
often
found
pulmonari
infect
upper
respiratori
viral
infect
detect
number
laboratori
modal
includ
cultur
direct
fl
uoresc
antigen
dfa
test
rapid
commerci
antigen
detect
kit
comprehens
multiplex
pcr
panel
becom
increasingli
util
mani
center
includ
sinc
techniqu
offer
greater
sensit
standard
modal
detect
coinfect
fact
mani
patient
develop
prolong
shed
particularli
steroid
also
suggest
pcrbase
method
may
enhanc
infect
control
practic
invas
diagnost
modal
also
need
diagnos
patient
bal
consid
patient
pulmonari
fi
nding
cultur
cytolog
antigen
test
eg
gm
bal
provid
addit
microbiolog
evid
avoid
institut
empir
therapi
see
tabl
addit
modal
may
help
evalu
nonfung
infect
separ
specifi
c
pathogen
detect
coinfect
provid
sampl
antimicrobi
resist
test
pcrbase
strategi
specifi
c
fungal
pathogen
still
develop
pcrbase
respiratori
test
viral
pathogen
bal
sampl
becom
standard
mani
center
pcp
classic
diagnos
induc
sputum
sampl
immunocompromis
popul
eg
hiv
howev
bronchoscopi
may
enhanc
diagnosi
transplant
recipi
due
low
burden
diseas
cmv
shell
vial
assay
cultur
bal
also
necessari
criteria
diagnosi
cmv
pneumonia
microbiolog
diagnosi
import
allow
target
treatment
help
determin
durat
therapi
diagnosi
pulmonari
process
made
bal
videoassist
thoracoscop
biopsi
vat
ctguid
biopsi
may
necessari
determin
caus
pulmonari
symptom
sinu
infect
otolaryngolog
evalu
obtain
highrisk
patient
sinu
symptom
earli
nasalsinu
endoscopi
visual
inspect
biopsi
allow
prompt
diagnosi
bacteri
pneumonia
treat
possibl
direct
cultur
sensit
tabl
treatment
guidelin
communityacquir
pneumonia
review
mandel
recommend
treatment
nosocomi
ventilatorassoci
pneumonia
review
american
thorac
societi
infecti
diseas
societi
america
particular
pseudomona
pneumonia
may
requir
prolong
treatment
due
high
risk
fatal
relaps
similar
cn
diseas
nocardia
pulmonari
diseas
treat
trimethoprimsulfamethoxazol
base
microbiolog
sensit
least
current
strategi
use
center
may
appropri
center
b
koh
prepar
dissolv
keratin
cellular
specimen
calcofl
uor
fl
oresc
dye
bind
polysaccharid
chitin
fungi
c
pcr
fungal
pathogen
standard
current
consid
part
standard
diagnost
test
fungal
diagnos
specifi
c
coronaviru
speci
associ
clinic
diseas
e
includ
parainfl
uenza
month
patient
legionella
pneumonia
receiv
week
respiratori
fl
uoroquinolon
azithromycin
aspergillu
pulmonari
infect
frequent
treat
voriconazol
lipid
amphotericin
b
formul
treatment
guidelin
review
walsh
lack
random
clinic
trial
compar
differ
agent
role
combin
therapi
controversi
result
futur
trial
address
combin
therapi
forthcom
patient
typic
undergo
therapi
pulmonari
nodul
complet
resolv
stabil
month
immunosuppress
therapi
patient
mucoral
pulmonari
infect
treat
either
lipid
amphotericin
b
formul
posaconazol
possibl
sensit
test
help
tailor
therapi
cardiothorac
surgeri
consult
consid
patient
fail
therapi
consid
adjunct
treatment
patient
solitari
fungal
nodul
treatment
less
frequent
fungal
infect
eg
scedosporium
speci
base
sensit
test
endem
fungal
cn
infect
treatment
option
review
refer
wheat
et
al
galgiani
et
al
perfect
et
al
patient
develop
pulmonari
cmv
receiv
iv
ganciclovir
foscarnet
addit
intraven
immunoglobulin
ivig
least
week
treatment
option
review
boeckh
adenoviru
pneumonia
approv
therapi
mani
center
attempt
iv
cidofovir
ivig
although
neither
studi
prospect
treatment
option
patient
infl
uenza
review
casper
usual
includ
oseltamivir
inhal
zanamivir
primari
therapi
altern
combin
therapi
consid
patient
lifethreaten
infect
particularli
sinc
develop
resist
occur
therapi
rsv
respons
aerosol
ribavirin
shown
reduc
mortal
lower
tract
diseas
surviv
may
improv
aerosol
ribavirin
use
combin
therapi
intraven
immunoglobulin
palivizumab
option
exist
treatment
viral
respiratori
pathogen
although
random
data
exist
oral
inhal
ribavirin
consid
patient
parainfl
uenza
metapneumoviru
cardiac
infect
rel
infrequ
patient
undergo
therapi
leukemia
diagnost
clue
cardiovascular
infect
develop
persist
posit
blood
cultur
patient
receiv
appropri
antimicrobi
therapi
continu
posit
cultur
remov
hardwar
eg
central
cathet
evalu
cardiac
vascular
sourc
infect
eg
endocard
aortiti
infect
thrombophleb
addit
patient
cardiovascular
infect
present
tachycardia
arrhythmia
acut
heart
block
heart
failur
myocardi
infarct
pain
phlebiti
limb
swell
two
common
infect
associ
cardiopulmonari
system
septic
thrombophleb
endocard
septic
thrombophleb
typic
involv
develop
bacteremia
fungemia
infect
preexist
thrombu
typic
site
line
placement
candida
speci
commonli
associ
phenomenon
bacteria
lead
complic
endocard
popul
uncommon
outcom
follow
transplant
case
often
due
streptococcu
staphylococcu
enterococc
speci
rare
gnr
atyp
organ
occasion
report
nearli
case
involv
right
side
heart
unless
patient
known
underli
valvular
patholog
candida
fungal
endocard
rare
associ
high
rate
morbid
mortal
interestingli
noninfecti
etiolog
endocardi
mass
thrombi
marant
chang
lead
similar
symptom
popul
invas
fungal
infect
myocardium
also
occur
associ
primari
pulmonari
involv
dissemin
rare
bacteri
fungal
process
lead
purul
pericard
viral
cardiac
complic
uncommon
patient
treat
leukemia
rare
case
herpesvirus
sporad
communityacquir
viral
infect
pericard
myocard
report
noninfecti
etiolog
advers
drug
side
effect
signifi
cantli
like
caus
infl
ammatori
heart
diseas
blood
cultur
remain
stapl
diagnosi
cardiovascular
infect
patient
recurr
bacteremia
either
immedi
complet
antibiot
therapi
consid
imag
rule
septic
thrombophleb
ultrasound
evalu
vein
near
either
site
line
placement
involv
edemat
limb
help
identifi
suspici
thrombi
patient
clinic
symptom
concern
endocard
undergo
electrocardiogram
echocardiographi
transthorac
echocardiographi
help
diagnos
rightsid
endocard
transesophag
echocardiographi
higher
sensit
leftsid
lesion
pursu
consid
high
risk
guidelin
diagnosi
treatment
manag
infect
endocard
found
baddour
cardiac
mri
may
use
diagnos
invas
fungal
infect
biopsi
gold
standard
diagnosi
mani
patient
invas
cardiac
mould
infect
diagnos
autopsi
patient
infect
thrombophleb
receiv
extend
antibiot
therapi
base
antimicrobi
sensit
test
organ
addit
prolong
antibiot
therapi
anticoagul
surgic
thrombu
remov
may
necessari
cure
patient
endocard
need
appropri
antibiot
week
follow
bacteri
clearanc
patient
develop
addit
complic
heart
failur
fail
antibiot
therapi
may
need
valv
replac
patient
candida
fungal
endocard
need
cardiothorac
surgic
consult
recov
without
surgic
valv
replac
treatment
followup
patient
endocard
review
detail
baddour
patient
invas
cardiac
fungal
infect
poor
prognosi
antifung
therapi
attempt
gastrointestin
gi
symptom
frequent
treatment
leukemia
consequ
chemotherapi
advers
reaction
gvhd
infect
diarrhea
exampl
occur
nearli
patient
posttranspl
period
surprisingli
diffi
cult
separ
infecti
noninfecti
etiolog
typic
gi
symptom
associ
infect
abdomin
perirect
pain
diarrhea
nausea
vomit
dysphagia
gi
bleed
sign
infecti
gi
process
also
includ
elev
temperatur
tachycardia
jaundic
liver
enzym
abnorm
mani
also
seen
noninfecti
etiolog
gvhd
sinusoid
obstruct
syndrom
bacteri
gi
complic
occur
treatment
leukemia
transplant
process
communityacquir
bacteri
caus
diarrhea
salmonella
shigella
occur
sporad
due
limit
oral
intak
less
frequent
exposur
standard
prophylact
antibiot
therapi
frequent
infecti
etiolog
diarrhea
clostridium
diffi
cile
infect
use
broadspectrum
antibiot
therapi
prolong
exposur
inpati
care
increas
risk
c
diffi
cile
usual
c
diffi
cile
associ
diarrhea
occur
within
fi
rst
day
posttranspl
patient
risk
transplant
process
episod
c
diffi
cile
occur
neutropenia
develop
lifethreaten
diseas
neutropen
enterocol
typhliti
present
triad
right
lower
quadrant
pain
diarrhea
fever
patient
sever
diseas
may
rebound
tender
sign
periton
fig
condit
involv
cecum
relat
loss
integr
bowel
wall
subsequ
bacteri
invas
classic
condit
associ
clostridium
septicum
like
involv
anaerob
organ
well
perirect
abscess
occur
earli
condit
mucos
neutropen
patient
may
present
minim
swell
erythema
high
index
suspicion
need
patient
rectal
pain
necrot
fasciiti
rule
patient
perin
involv
see
skin
soft
tissu
section
intraabdomin
hepat
abscess
infrequ
oral
candidiasi
thrush
frequent
complic
follow
transplant
much
less
common
addit
fl
uconazol
prevent
strategi
thrush
occur
result
azoleresist
speci
candida
esophag
less
underw
ct
scan
abdomen
demonstr
bowel
wall
thicken
edema
throughout
cecum
ascend
colon
surround
fat
strand
yellow
arrow
consist
neutropen
enterocol
typhliti
blood
cultur
day
admiss
posit
c
septicum
patient
improv
broadspectrum
antibiot
therapi
need
surgic
intervent
frequent
primarili
due
c
albican
reliabl
sensit
fl
uconazol
candida
speci
primarili
c
albican
also
present
involv
liver
hepatosplen
candidiasi
patient
hepatosplen
candidiasi
acquir
diseas
period
neutropenia
may
develop
fever
right
upper
quadrant
pain
increas
liver
function
test
neutrophil
recoveri
patient
hepatosplen
candidiasi
normal
detect
candidemia
nearli
case
thought
due
c
albican
similar
invas
candida
complic
hepatosplen
candidiasi
becom
less
common
sinc
addit
standard
fl
uconazol
prophylaxi
mould
involv
gut
devast
complic
mould
infect
gi
tract
thought
acquir
ingest
period
high
risk
unfortun
invas
infect
diffi
cult
diagnosi
premortem
due
nonspecifi
c
symptom
imag
fig
patient
typic
present
abdomin
pain
other
fever
nonspecifi
c
fi
nding
gi
bleed
perfor
late
sign
invas
involv
frequent
gi
mould
aspergillu
speci
mucoral
lead
diseas
throughout
gi
tract
includ
liver
clinic
diagnosi
challeng
delay
lead
high
rate
mortal
mani
diagnos
autopsi
herpesvirus
particularli
cmv
lead
invas
diseas
throughout
gi
tract
cmv
gi
diseas
transplant
recipi
resembl
gut
gvhd
infrequ
found
biopsi
conjunct
gut
gvhd
diagnosi
patient
typic
present
abdomin
pain
diarrhea
lower
tract
nausea
earli
satieti
upper
tract
patient
either
highdos
steroid
tcelldeplet
transplant
recipi
major
patient
cmv
detect
blood
time
diagnosi
sinc
signifi
cant
proport
blood
dissemin
neg
plasma
pcr
preclud
invas
cmv
diseas
gi
diseas
common
site
late
cmv
diseas
cmv
rare
lead
sever
hepat
hsv
caus
eros
esophag
hepat
routin
use
acyclovir
prophylaxi
limit
complic
vzv
reactiv
lead
gi
diseas
viscer
varicellazost
uniqu
popul
lifethreaten
condit
necessit
treatment
highdos
iv
acyclovir
complic
must
consid
leukem
transplant
patient
present
triad
abdomin
pain
increas
liver
function
test
hyponatremia
patient
viscer
involv
also
present
hepat
pancreat
compon
diagnosi
importantli
unlik
episod
vzv
reactiv
present
alway
associ
rash
skin
lesion
usual
associ
herp
zoster
empir
therapi
start
immedi
diagnosi
suspect
ebv
posttranspl
recipi
caus
ptld
highrisk
patient
occur
hct
patient
ptld
present
anywher
predilect
gut
liver
symptom
vari
locat
gi
diseas
challeng
diagnos
risk
factor
develop
ebvassoci
complic
includ
tcell
deplet
ebv
serolog
mismatch
splenectomi
mismatch
unrel
transplant
develop
chronic
gvhd
ptld
peak
around
month
posttranspl
polymorph
diseas
umbil
cord
blood
transplant
recipi
may
like
develop
earli
malign
monomorph
diseas
interestingli
patient
age
increas
rate
ptld
adenoviru
frequent
lead
develop
diarrhea
sever
case
lower
tract
gi
bleed
dissemin
strong
correl
detect
viremia
develop
invas
diseas
adenoviru
reactiv
occur
frequent
patient
mismatch
graft
receiv
tcelldeplet
transplant
children
adenoviru
occur
frequent
earlier
posttranspl
invas
diseas
preval
adenoviru
lead
hepat
fulmin
hepat
failur
noroviru
norwalk
agent
increasingli
recogn
major
caus
morbid
mortal
cancer
patient
patient
like
develop
chronic
diarrhea
associ
signifi
cant
weight
loss
need
parenter
nutrit
patient
develop
noroviru
commun
like
shed
viru
extend
period
time
make
infect
control
practic
critic
prevent
rotaviru
also
recogn
potenti
pathogen
final
hepat
b
hbv
major
problem
patient
prior
exposur
treatment
leukemia
patient
quiescent
hbv
hbsag
posit
occult
hbv
develop
reactiv
develop
hepat
even
fulmin
liver
failur
prophylaxi
treatment
patient
prior
histori
hbv
led
fewer
complic
relat
diseas
hepat
c
hcv
also
known
caus
longterm
complic
transplant
recipi
may
also
associ
develop
sinusoid
obstruct
syndrom
patient
develop
gi
symptom
particularli
diarrhea
abdomin
pain
evalu
infecti
etiolog
routin
bacteri
cultur
parasit
examin
rare
use
pathogen
uncommon
sampl
howev
routin
sent
c
diffi
cile
test
regardless
prior
antibiot
exposur
elev
liver
transaminas
alkalin
phosphatas
rise
bilirubin
also
suggest
potenti
etiolog
viral
test
includ
adenoviru
pcr
noroviru
pcr
rotaviru
eia
stool
consid
patient
patient
known
hbv
exposur
hbv
pcr
baselin
develop
sever
transamin
repeat
addit
although
cmv
ebv
adenoviru
pcr
serum
suggest
underli
diagnosi
vzv
hsv
pcr
serumplasma
face
symptom
consist
viscer
zoster
acut
hepat
critic
import
diagnosi
serum
gm
sent
patient
felt
risk
gutrel
aspergillu
may
fals
posit
patient
sever
mucos
breakdown
receiv
piperacillintazobactam
therapi
patient
receiv
intens
chemotherapi
baselin
serolog
test
viral
hepat
patient
abdomin
pain
ct
scan
abdomen
pelvi
help
evalu
potenti
etiolog
assess
perfor
abscess
may
help
identifi
diseas
classic
appear
ct
hepatosplen
candidiasi
exampl
present
multipl
hypodens
bull
eye
lesion
liver
spleen
indic
candida
abscess
within
liver
neutropen
enterocol
typic
demonstr
infl
ammat
strand
around
cecum
fig
unfortun
gi
mould
infect
may
diffi
cult
diagnos
imag
mani
diagnos
follow
death
fig
intervent
may
also
import
workup
patient
symptom
patient
risk
gvhd
gastroenterolog
consult
suggest
evalu
endoscopi
endoscop
visual
biopsi
help
differenti
viral
infect
cmv
adenoviru
gvhd
may
detect
infecti
lesion
import
stress
one
diagnost
method
cmv
detect
need
gi
tract
cmv
pcr
still
need
valid
diagnost
entiti
diagnosi
surgic
intervent
liver
biopsi
may
necessari
particularli
patient
without
clear
diagnosi
ct
fi
nding
suspici
fungal
process
patient
sever
neutropen
enterocol
sever
abdomin
pain
may
need
emerg
surgic
consult
patient
develop
c
diffi
cile
infect
treat
either
oral
metronidazol
oral
vancomycin
tabl
patient
sever
infect
may
better
outcom
oral
vancomycin
patient
neutropen
enterocol
perirect
infect
receiv
broadspectrum
antibiot
cover
anaerob
speci
eg
metronidazol
gnr
surgic
consult
pursu
patient
condit
patient
may
need
earli
surgic
intervent
patient
invas
candida
infect
receiv
prolong
fl
uconazol
echinocandin
therapi
patient
diagnos
invas
mould
receiv
mouldact
therapi
depend
pathogen
identifi
ed
voriconazol
lipid
amphotericin
b
formul
posaconazol
commonli
use
agent
patient
also
surgic
consult
cmv
infect
treat
ganciclovir
foscarnet
hsvvzv
infect
highdos
iv
acyclovir
patient
develop
ptld
hct
often
treat
rituximab
may
need
addit
chemotherapi
option
exist
noroviru
therapi
nitazoxanid
may
option
treatment
hbv
review
detail
lok
typic
entail
lamivudin
entecavir
adefovir
patient
genitourinari
gu
infect
treatment
leukemia
often
present
symptom
similar
immunocompet
patient
urinari
frequenc
dysuria
fl
ank
pain
hematuria
fever
patient
risk
addit
complic
like
develop
renal
dysfunct
invas
infect
addit
side
effect
numer
medic
chemoth
broadspectrum
antibiot
continu
febril
increas
abdomin
distent
increas
bilirubin
despit
aggress
antibiot
underw
ct
scan
abdomen
demonstr
moder
ascit
pneumoperitoneum
obstruct
identifi
ed
patient
develop
respiratori
distress
anasarca
dens
pulmonari
infi
ltrate
autopsi
found
dissemin
intraabdomin
rhizopu
speci
mould
invad
celiac
axi
thrombosi
also
involv
liver
diaphragm
stomach
pancrea
spleen
adren
gland
api
agent
eg
cyclophosphamid
calcineurin
inhibitor
lead
addit
gu
toxic
need
urinari
cathet
highli
compromis
patient
may
also
increas
risk
combin
advers
drug
toxic
gvhd
sepsi
subsequ
multiorgan
failur
lead
renal
failur
need
acut
renal
replac
therapi
patient
receiv
standard
therapi
leukemia
patient
undergo
transplant
risk
develop
urinari
tract
infect
uti
use
standard
prophylact
antibiot
limit
uti
somewhat
led
develop
resist
nosocomi
infect
particularli
patient
prolong
hospit
catheter
patient
undergo
leukemia
therapi
escherichia
coli
klebsiella
pneumonia
predomin
speci
detect
urinari
sampl
patient
urinari
cathet
import
separ
colon
symptomat
infect
patient
also
develop
complic
kidney
septic
emboli
invas
infect
kidney
bladder
occur
infrequ
fungal
infect
pelvic
organ
rel
infrequ
phenomenon
candida
frequent
organ
infect
gu
tract
urinari
tract
infect
typic
present
invas
candid
abscess
occur
episod
candidemia
patient
develop
candiduria
typic
anatom
abnorm
gu
tract
treat
broadspectrum
antibiot
urinari
cathet
candid
organ
also
lead
asymptomat
colon
urinari
cathet
case
invas
diseas
gu
tract
infect
uncommon
manifest
mould
infect
patient
aspergillu
infect
infrequ
develop
parenchym
involv
dissemin
infect
occasion
seen
isol
infect
bladder
kidney
mucoral
less
common
fungal
speci
also
rare
report
caus
invas
diseas
genitourinari
tract
bk
viru
frequent
reactiv
genitourinari
system
immunosuppress
lead
develop
hemorrhag
cystiti
hc
mani
patient
detect
bk
viru
urin
may
asymptomat
develop
bkassoci
hc
present
frequent
urin
fl
ank
pain
frank
hematuria
sever
case
develop
sever
infl
ammat
clot
bladder
lead
urinari
obstruct
rare
bk
lead
nephriti
hct
recipi
interestingli
immun
respons
bk
may
play
import
role
develop
bkassoci
symptom
adenoviru
also
lead
hc
common
caus
nephriti
bk
unlik
bk
viru
risk
factor
develop
invas
adenoviru
includ
major
chang
immun
function
includ
tcell
deplet
adenoviru
genitourinari
infect
also
known
common
children
patient
mismatch
graft
standard
urinalysi
urin
blood
cultur
import
compon
workup
patient
urinari
symptom
urin
cultur
result
must
interpret
caution
patient
urinari
cathet
separ
colon
versu
invas
diseas
challeng
review
nicol
viral
pcr
adenoviru
bk
blood
urin
help
evalu
patient
either
hc
andor
renal
failur
bk
viral
load
serum
copiesml
may
predict
patient
bkassoci
hc
ultrasound
ct
imag
may
also
help
determin
invas
fungal
infect
concern
possibl
nephriti
fungal
infect
kidney
biopsi
bladder
cystoscopi
may
necessari
make
defi
nitiv
diagnosi
bacteri
infect
typic
requir
focus
therapi
base
sensit
test
length
therapi
depend
sever
infect
tabl
patient
cathet
replac
prior
start
therapi
possibl
candida
infect
treat
fl
uconazol
echinocandin
therapi
lipid
amphotericin
b
formul
depend
sensit
test
amphotericin
bladder
wash
use
center
adjunct
therapi
patient
known
colon
patient
invas
mould
infect
receiv
voriconazol
lipid
amphotericin
b
formul
posaconazol
depend
pathogen
identifi
ed
patient
also
urolog
consult
bkvirusrel
diseas
diffi
cult
treat
particularli
sinc
reduct
immunosuppress
possibl
patient
sever
diseas
cidofovir
lefl
unomid
ivig
fl
uoroquinolon
suggest
possibl
therapeut
option
random
trial
exist
adenoviru
hc
nephriti
diffi
cult
treat
iv
cidofovir
attempt
leukemia
patient
present
myriad
skin
soft
tissu
manifest
clue
underli
infecti
etiolog
examin
transplant
patient
receiv
therapi
leukemia
import
good
skin
exam
cutan
infect
present
wide
varieti
visual
appear
nodul
ulcer
eschar
petechia
rasherythema
andor
pustul
patient
present
fever
pain
suggest
invas
process
depend
appear
distribut
cutan
fi
nding
help
make
diagnosi
eg
dermatom
herp
zoster
mani
import
noninfecti
etiolog
drug
side
effect
gvhd
leukemia
cuti
neutrophil
dermatosi
sweet
syndrom
mimic
infecti
etiolog
regardless
notabl
lesion
rash
promptli
evalu
cellul
common
manifest
bacteri
infect
major
cellul
case
due
streptococcu
staphylococcu
speci
frequent
bacteri
etiolog
identifi
ed
certain
bacteri
speci
present
specifi
c
skin
manifest
pseudomona
gnr
present
ecthyma
gangrenosum
earli
stage
appear
bulla
later
slough
classic
form
gangren
ulcer
black
eschar
c
jeikeium
often
present
erythemat
papular
erupt
episod
bacteremia
nocardia
uncommon
organ
also
led
cutan
manifest
popul
gangren
necrot
fasciiti
lifethreaten
skin
infect
character
necrosi
deeper
subcutan
fat
fascia
patient
typic
present
sign
overwhelm
infect
rate
mortal
high
leukemia
necrot
fasciiti
either
polymicrobi
process
caus
singular
primarili
gnr
speci
patient
may
present
bacteremia
minim
skin
fi
nding
may
progress
rapidli
fulmin
cours
clue
diagnosi
includ
rapidli
expand
cellul
blackduski
area
involv
pain
proport
cutan
fi
nding
laboratori
alter
elev
creatinin
lactic
acidosi
surgic
consult
immedi
debrid
affect
area
mandatori
specifi
c
form
necrot
fasciiti
involv
perineum
fournier
gangren
particularli
morbid
fungal
skin
lesion
transplant
similar
bacteri
counterpart
candida
speci
one
common
fungal
infect
dermatolog
manifest
candidemia
present
cm
scatter
erythemat
papular
nodul
pale
center
cryptococcu
also
lead
skin
nodul
dissemin
diseas
solitari
nodul
like
caus
mould
typic
aspergillu
mucoral
initi
subtl
present
mould
infect
occur
site
trauma
site
bone
marrow
biopsi
iv
placement
typic
lesion
progress
rapidli
without
appropri
treatment
fusarium
one
mould
present
frequent
dermatolog
manifest
usual
appear
greater
patient
dissemin
fusariosi
typic
lesion
erythemat
macul
papul
gray
necrot
ulcer
center
patient
cutan
fungal
infect
undergo
evalu
identifi
other
site
infect
hsv
commonli
associ
vesicular
lesion
either
around
oropharynx
typic
around
anogenit
region
lesion
period
sever
immunosuppress
much
sever
typic
present
erythemat
vesicl
dew
drop
rose
petal
standard
use
acyclovir
prophylaxi
episod
hsv
transplant
leukemia
therapi
less
frequent
although
acyclovirresist
case
occasion
occur
especi
lowdos
regimen
similar
hsv
vzv
present
herp
zoster
dissemin
diseas
typic
dermatom
reactiv
occur
late
transplant
activ
chemotherapi
postcondit
patient
risk
dissemin
appear
unlik
primari
varicella
chickenpox
erythemat
rash
seen
viral
infect
infect
blood
cultur
help
identifi
underli
etiolog
skin
infect
dermatolog
consult
biopsi
also
help
make
diagnosi
may
necessari
case
larg
differenti
diagnosi
patient
lesion
suspici
invas
fungal
infect
undergo
routin
biopsi
patient
increas
concern
necrot
fasciiti
high
lactat
abnorm
chemistri
panel
low
co
elev
creatinin
also
suggest
diagnosi
must
confi
rmed
visual
inspect
fascia
patholog
review
urgent
surgic
consult
requir
patient
lesion
consist
hsv
vzv
lesion
unroof
sampl
base
lesion
sent
dfa
shell
vial
pcr
hsv
vzv
pcr
level
serum
also
sent
patient
appear
dissemin
diseas
bacteri
cellul
often
treat
empir
regimen
patient
rare
known
caus
organ
vancomycin
often
ad
gramposit
coverag
gnr
treatment
ad
case
sever
infect
patient
identifi
ed
pathogen
therapi
focus
sensit
pattern
organ
tabl
patient
evid
necrot
fasciiti
must
undergo
immedi
surgic
consult
debrid
broad
coverag
recommend
empir
therapi
await
oper
room
fungal
infect
treat
fl
uconazol
echinocandin
voriconazol
lipid
amphotericin
b
formul
posaconazol
depend
speci
sensit
sever
diseas
patient
invas
aspergillu
mucoral
speci
mould
need
extens
surgic
debrid
cure
infect
patient
local
hsv
vzv
reactiv
treat
highdos
acyclovir
valacyclovir
guidelin
review
freifeld
tomblyn
baden
neutropen
fever
one
common
complic
follow
therapi
patient
leukemia
occur
greater
patient
undergo
treatment
fever
caus
numer
etiolog
patient
document
infect
neutropen
evalu
howev
due
high
risk
morbid
mortal
associ
infect
provid
give
standard
prophylaxi
period
risk
numer
risk
categori
review
detail
freifeld
et
al
prevent
strategi
differ
slightli
group
patient
receiv
therapi
leukemia
transplant
recipi
expect
prolong
period
neutropenia
day
consid
higher
risk
center
guidelin
recommend
use
fl
uoroquinolon
prophylaxi
popul
appear
effect
iv
ceftazidim
due
emerg
fl
uoroquinoloneresist
viridan
particularli
ciprofl
oxacin
center
add
addit
penicillin
vk
amoxicillin
fl
uoroquinolon
other
earli
vancomycin
patient
high
risk
organ
trimethoprimsulfamethoxazol
consid
patient
allergi
fl
uoroquinolon
often
possibl
patient
neutropenia
prophylaxi
stop
neutrophil
recoveri
late
strategi
prevent
posttranspl
pneumonia
encapsul
bacteria
patient
chronic
gvhd
base
local
resist
pattern
sinc
vre
mrsa
major
problem
treatment
phase
leukemia
therapi
standard
screen
vre
rectal
mrsa
nasal
recommend
prior
start
chemotherapi
due
increas
risk
signifi
cant
morbid
associ
fungal
infect
center
use
standard
antifung
prophylaxi
fluconazol
prophylaxi
shown
decreas
rate
major
fungal
infect
major
effect
prevent
invas
candida
breakthrough
candidemia
prophylact
fl
uconazol
occur
typic
form
c
glabrata
c
krusei
echinocandin
particularli
micafungin
shown
use
altern
agent
voriconazol
prophylaxi
shown
equival
fl
uconazol
patient
undergo
myeloabl
hct
signifi
cantli
reduc
number
aspergillu
infect
followup
random
trial
increas
mucoral
speci
seen
posaconazol
prophylaxi
shown
decreas
risk
invas
mould
infect
highrisk
patient
gvhd
patient
neutropenia
limit
protonpump
inhibitor
use
coadministr
food
acid
beverag
increas
dose
may
prevent
develop
insuffi
cient
drug
level
subsequ
breakthrough
infect
drug
level
consid
patient
receiv
voriconazol
posaconazol
prophylaxi
pcp
prevent
also
import
compon
posttranspl
prevent
prefer
agent
prevent
postengraft
trimethoprimsulfamethoxazol
trimethoprimsulfamethoxazol
prefer
superior
prevent
agent
crossprotect
toxoplasmosi
nocardia
patient
known
allergi
sulfa
drug
attempt
desensit
attempt
secondlin
agent
includ
dapson
atovaquon
aerosol
pentamidin
pentamidin
clearli
inferior
atovaquon
studi
prospect
two
major
prevent
strategi
current
use
practic
prevent
develop
cmv
diseas
primari
antivir
prophylaxi
preemptiv
therapi
fig
clinic
trial
ganciclovir
prophylaxi
perform
shown
decreas
cmv
diseas
prophylact
approach
ganciclovir
caus
neutropenia
increas
suscept
bacteri
fungal
infect
prolong
exposur
cmvspecifi
c
antivir
agent
particularli
minim
immun
pressur
subclin
reactiv
lead
select
drugresist
cmv
mani
transplant
center
preemptiv
therapi
use
cmv
prevent
hct
although
preemptiv
strategi
similar
center
specifi
c
cutoff
start
therapi
vari
center
institut
transplant
recipi
monitor
weekli
cmv
viremia
quantit
realtim
serum
pcr
fi
rst
day
posttranspl
center
use
cmv
antigenemia
whole
blood
pcr
assay
patient
detect
cmv
progress
diseas
center
need
develop
viral
load
threshold
pcr
antigenemia
maxim
effect
minim
toxic
altern
center
use
combin
strategi
primari
prophylaxi
highdos
acyclovir
addit
preemptiv
therapi
day
posttranspl
pcr
surveil
may
discontinu
lowrisk
patient
highrisk
patient
particularli
ongo
gvhd
therapi
continu
weekli
surveil
late
cmv
diseas
reach
minim
immunosuppress
level
least
three
consecut
neg
weekli
test
late
surveil
threshold
initi
therapi
copi
ml
greater
fi
vefold
increas
viral
load
patient
establish
baselin
center
screen
highrisk
posttranspl
patient
eg
tcelldeplet
transplant
weekli
ebv
pcr
numer
test
strategi
advoc
includ
whole
blood
pbmc
cellfre
plasma
gener
specimen
provid
good
sensit
although
comparison
suggest
cellfre
plasma
may
provid
superior
specifi
citi
ptld
author
favor
preemptiv
therapi
similar
seen
cmv
detect
ebv
dna
level
certain
threshold
trigger
reduct
immunosuppress
rituximab
therapi
current
guidelin
threshold
ebv
viremia
due
varianc
test
transplant
popul
group
use
prompt
therapi
treatment
trigger
detect
ebv
dna
accompani
overt
sign
ebv
diseas
prompt
therapi
shown
similar
effi
caci
preemptiv
therapi
base
concern
delay
treatment
may
lead
increas
complic
mani
group
still
favor
preemptiv
approach
tcell
immunotherapeut
regimen
still
experiment
wide
avail
studi
use
moderateand
lowdos
acyclovir
posttranspl
period
demonstr
mark
decreas
vzv
hsv
complic
use
acyclovir
valacyclovir
recommend
least
one
year
posttranspl
month
cessat
immunosuppress
therapi
longterm
prophylaxi
also
appear
prevent
emerg
acyclovirresist
hsv
lowdos
acyclovir
also
shown
abil
prevent
hsv
vzv
reactiv
smaller
studi
gener
surveil
recommend
lowrisk
patient
preemptiv
monitor
advoc
adenoviru
particularli
children
undergo
transplant
highrisk
adult
eg
tcelldeplet
transplant
recipi
often
cidofovir
use
agent
choic
preemptiv
therapi
sever
nonrandom
studi
support
use
prophylact
palivizumab
children
year
throughout
rsv
season
adult
receiv
palivizumab
prophylaxi
drug
ganciclovir
iv
oral
usual
given
point
patient
engraft
mani
center
use
antigenemiabas
preemptiv
test
strategi
larg
mediumgray
arrow
start
earlier
shown
prevent
cmv
diseas
pcrbase
preemptiv
therapi
larg
white
arrow
standard
mani
center
includ
allow
test
begin
immedi
condit
small
white
arrow
indic
weekli
test
pcr
center
least
day
small
gray
arrow
indic
weekli
antigenemia
test
typic
start
near
engraft
